SLC5A2 and hydrops fetalis: This consistent evidence of therapeutic benefits of SGLT2 inhibitors on a broad spectrum of cardiorenal endpoints in large RCTs should lead to the recommendation of these agents in updated ADA, AACE, ACC, AHA, and ESC guidelines as first-line treatments for atherosclerotic cardiovascular disease and HF.